middle.news
CSL Bets $117M on VarmX’s Breakthrough Coagulation Therapy
8:09am on Tuesday 16th of September, 2025 AEST
•
Healthcare
Read Story
CSL Bets $117M on VarmX’s Breakthrough Coagulation Therapy
8:09am on Tuesday 16th of September, 2025 AEST
Key Points
CSL invests US$117 million upfront for exclusive acquisition option
VMX-C001 targets severe bleeding in 20 million global FXa inhibitor patients
FDA grants Fast Track designation recognizing urgent medical need
CSL to fund global Phase 3 trial and support late-stage development
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL
OPEN ARTICLE